FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Agency Reference Model Suggested for Next Level Preemption

[ Price : $8.95]

A law journal article, discussed in Regulatory Review, proposes a framework courts could use to consider state challenges to feder...

3 Former Magellan Execs Sentenced

[ Price : $8.95]

The Department of Justice says a Massachusetts federal judge sentenced three former Magellan Diagnostics executives for hiding a m...

Quality System Violations at Hong Qiangxing Electronics

[ Price : $8.95]

FDA warns Chinas Hong Qiangxing Shenzhen Electronics about Quality System violations in its production of several medical devices....

Owen Biosciences CGMP Violations

[ Price : $8.95]

FDA warns Baton Rouge, LA-based Owen Biosciences about CGMP violations in its production of finished drugs as a contract manufactu...

Gene Therapy for Broader Spinal Muscular Atrophy Range

[ Price : $8.95]

FDA approves Novartis Itvisma (onasemnogene abeparvovec-brve), a new formulation of a gene therapy for a broader age of spinal mus...

Guidance on Where to Submit Cross-Center Master Files

[ Price : $8.95]

FDA issues a draft guidance with recommendations to help master file holders determine to which Center to submit cross-Center mast...

Makary Missing the Point on Advisory Committees: Zuckerman

[ Price : $8.95]

National Center for Health Research president Diana Zuckerman defends FDA advisory committees, saying they do a more thorough job ...

Amycretin Sees 14.5% Weight Loss in Phase 2 Diabetes Trial

[ Price : $8.95]

Novo Nordisk reports favorable Phase 2 data for its investigational dual-action obesity and diabetes drug amycretin, showing signi...

Study Finds Public Speaker Conflicts at FDA Panel Meetings

[ Price : $8.95]

A new study of FDA advisory committee meetings reveals that a substantial portion of public speakers support drug approval, and ma...

Catalent Indiana FDA-483 Has Six Observations

[ Price : $8.95]

FDA releases the form FDA-483 with six observations from an inspection at the Catalent Indiana sterile drug manufacturing facility...